RESUMO
A synthetic peptidemimetic substrate of the human immunodeficiency virus 1 (HIV-1) protease with a nonhydrolyzable pseudodipeptidyl insert at the protease cleavage site was prepared. The peptide U-81749 inhibited recombinant HIV-1 protease in vitro (inhibition constant Ki of 70 nanomolar) and HIV-1 replication in human peripheral blood lymphocytes (inhibitory concentration IC50 of 0.1 to 1 micromolar). Moreover, 10 micromolar concentrations of U-81749 significantly inhibited proteolysis of the HIV-1 gag polyprotein (p55) to the mature viral structural proteins p24 and p17 in cells infected with a recombinant vaccinia virus expressing the HIV-1 gag-pol genes. The HIV-1 like particles released from inhibitor-treated cells contained almost exclusively p55 and other gag precursors, but not p24. Incubation of HIV-like particles recovered from drug-treated cultures in drug-free medium indicated that inhibition of p55 proteolysis was at least partially reversible, suggesting that U-81749 was present within the particles.
Assuntos
Antivirais/farmacologia , Endopeptidases/metabolismo , HIV-1/efeitos dos fármacos , Oligopeptídeos/farmacologia , Inibidores de Proteases/farmacologia , Sequência de Aminoácidos , DNA Viral/genética , Proteínas de Fusão gag-pol/genética , Proteínas de Fusão gag-pol/metabolismo , Produtos do Gene gag/metabolismo , Protease de HIV , HIV-1/genética , HIV-1/fisiologia , Humanos , Linfócitos/microbiologia , Dados de Sequência Molecular , Estrutura Molecular , Precursores de Proteínas/metabolismo , RNA Viral/metabolismo , Transfecção , Replicação Viral/efeitos dos fármacosRESUMO
Evidence for a key role of beta-amyloid (Abeta) in Alzheimer's disease has led to considerable interest in potential therapeutic strategies targeting enzymes involved in processing the amyloid precursor protein (APP). Beta-site APP Cleaving Enzyme (BACE or beta-secretase) is a membrane bound aspartyl protease that has been shown to be directly involved in Abeta production and, therefore, is at the forefront of therapeutic targets in the treatment of Alzheimer's disease. BACE-2, an enzyme closely related to BACE, regulates Abeta production in a manner antagonistic to BACE, suggesting that non-selective inhibition of BACE-2 by BACE inhibitors might impair the lowering of Abeta. The design of BACE inhibitors that do not inhibit BACE-2 would be enhanced by structural and kinetic studies, efforts that typically demand considerable amounts of both enzymes. A BACE-2 construct containing 19 residues of the BACE prosegment followed by the BACE-2 catalytic domain sequence, Asp36-Trp447, was produced in E. coli inclusion bodies (IB) at 110-140 mg/L cell culture. Exploration of a variety of refolding conditions resulted in an efficient method for refolding the resulting pro-BACE-2 construct, and this protein undergoes facile autocatalytic cleavage, optimal at pH 4, at the Leu40- downward arrow-Ala41 bond. Refolded BACE-2 was purified by anion exchange, molecular sieve, and affinity chromatographies, yielding 105 mg of homogeneous enzyme (kcat/ Km = 1.2 x 10(4) x M(-1) x sec(-1)) from 8 liters of E. coli cell culture.
Assuntos
Secretases da Proteína Precursora do Amiloide/química , Ácido Aspártico Endopeptidases/química , Domínio Catalítico/genética , Sequência de Aminoácidos , Secretases da Proteína Precursora do Amiloide/genética , Secretases da Proteína Precursora do Amiloide/metabolismo , Ácido Aspártico Endopeptidases/genética , Ácido Aspártico Endopeptidases/metabolismo , Cromatografia de Afinidade , Clonagem Molecular , Escherichia coli/genética , Escherichia coli/metabolismo , Humanos , Corpos de Inclusão/metabolismo , Dados de Sequência Molecular , Dobramento de Proteína , Proteínas Recombinantes/química , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Análise de Sequência de Proteína , TemperaturaRESUMO
BACE, or beta-secretase, is an attractive target in the treatment of Alzheimer's Disease because of its involvement in the generation of amyloid beta peptides. BACE is a type I transmembrane aspartyl protease composed of pre-, pro-, catalytic, transmembrane and cytoplasmic domains. For the present study, the coding sequence was truncated just before the transmembrane domain and the resulting construct was extended with the C-terminal addition of a (His)(6) and expressed in several mammalian host cells. The enzyme expressed in CHO cells had the best crystallographic behavior and was purified in large quantities in a three step procedure. The purified BACE was comprised of two forms, namely the full length proBACE construct beginning with Thr(1), and a derivative missing the first 24 amino acids beginning with E(25). These BACE precursors co-crystallized in the presence of inhibitors yielding structures to 3.2 A resolution. HIV-1 protease treatment of this mixture resulted in complete cleavage of the F(39)-V(40) bond, leaving the V(40)EM...ES(432) (His)(6) derivative that was purified yielding an enzyme that was no more active than untreated BACE but co-crystallized with inhibitors producing well shaped, bipyramidal co-crystals diffracting to 2.6 A resolution.
Assuntos
Secretases da Proteína Precursora do Amiloide/isolamento & purificação , Ácido Aspártico Endopeptidases/isolamento & purificação , Protease de HIV/metabolismo , Precursores de Proteínas/isolamento & purificação , Doença de Alzheimer/metabolismo , Doença de Alzheimer/patologia , Sequência de Aminoácidos , Secretases da Proteína Precursora do Amiloide/genética , Secretases da Proteína Precursora do Amiloide/metabolismo , Animais , Ácido Aspártico Endopeptidases/genética , Ácido Aspártico Endopeptidases/metabolismo , Células CHO , Cricetinae , Cricetulus , Cristalização , Humanos , Dados de Sequência Molecular , Estrutura Molecular , Conformação Proteica , Precursores de Proteínas/genética , Precursores de Proteínas/metabolismo , Análise de Sequência de Proteína , Difração de Raios XRESUMO
BACE (beta-site APP cleaving enzyme) or beta-secretase, the enzyme responsible for processing APP to give the N-terminal portion of the Abeta peptide, is a membrane bound aspartyl protease consisting of an ectodomain catalytic unit, a C-terminal transmembrane segment and a cytoplasmic domain. Three BACE constructs, pET11a-BACE, pQE80L-BACE, and pQE70-BACE were designed to terminate at a position just before the transmembrane domain (Ser(432)) and are described schematically below. (1) pET11a-T7.Tag-G-S-M-(A-8GV......QTDES(432)), (2) pQE80L-Met-R-G-S-(His)(6)-G-S-I-E-T-D-(T(1)QH...QTDES(432)), and (3) pQE70-Met-BACE (R(36)GSFVEMG....PQTDES(432) (His) (6)) Each construct was over-expressed in Escherichia coli as inclusion bodies. The inclusion body proteins were solubilized in urea and refolded by dilution in water to yield active enzyme. Maximal activity for pET11a-BACE and pQE80L-BACE was usually reached at day 3 to 4, while construct pQE70-BACE required about 21 days. Active BACE was purified to homogeneity by anion-exchange chromatography and affinity chromatography over a column of immobilized peptide inhibitor. The process, easily scalable to 60 liters of cell culture, yielded in excess of 400 mg of active enzyme for crystallographic analysis. Highly purified pET11a-BACE and pQE70-BACE formed complexes with various inhibitors, the latter protein giving crystals diffracting up to 1.45 A resolution. In addition, a crystal form that does not require the presence of an inhibitor has been obtained for pQE70-BACE. This ligand-free crystal form has proven useful for the preparation of BACE-inhibitor complexes in soaking experiments.
Assuntos
Secretases da Proteína Precursora do Amiloide/isolamento & purificação , Ácido Aspártico Endopeptidases/isolamento & purificação , Dobramento de Proteína , Doença de Alzheimer/metabolismo , Doença de Alzheimer/patologia , Sequência de Aminoácidos , Secretases da Proteína Precursora do Amiloide/química , Secretases da Proteína Precursora do Amiloide/genética , Secretases da Proteína Precursora do Amiloide/metabolismo , Animais , Ácido Aspártico Endopeptidases/química , Ácido Aspártico Endopeptidases/genética , Ácido Aspártico Endopeptidases/metabolismo , Células CHO , Cricetinae , Cricetulus , Cristalização , Escherichia coli/genética , Escherichia coli/metabolismo , Protease de HIV/metabolismo , Humanos , Dados de Sequência Molecular , Estrutura Molecular , Conformação Proteica , Precursores de Proteínas/química , Precursores de Proteínas/genética , Precursores de Proteínas/metabolismo , Proteínas Recombinantes/química , Proteínas Recombinantes/genética , Proteínas Recombinantes/isolamento & purificação , Proteínas Recombinantes/metabolismo , Difração de Raios XRESUMO
BACKGROUND: Caspases are a family of cysteine proteases that have important intracellular roles in inflammation and apoptosis. Caspase-8 activates downstream caspases which are unable to carry out autocatalytic processing and activation. Caspase-8 is designated as an initiator caspase and is believed to sit at the apex of the Fas- or TNF-mediated apoptotic cascade. In view of this role, the enzyme is an attractive target for the design of inhibitors aimed at blocking the undesirable cell death associated with a range of degenerative disorders. RESULTS: The structure of recombinant human caspase-8, covalently modified with the inhibitor acetyl-Ile-Glu-Thr-Asp-aldehyde, has been determined by X-ray crystallography to 1.2 A resolution. The asymmetric unit contains the p18-p11 heterodimer; the biologically important molecule contains two dimers. The overall fold is very similar to that of caspase-1 and caspase-3, but significant differences exist in the substrate-binding region. The structure answers questions about the enzyme-inhibitor complex that could not be explained from earlier caspase structures solved at lower resolution. CONCLUSIONS: The catalytic triad in caspase-8 comprises Cys360, His317 and the backbone carbonyl oxygen atom of Arg258, which points towards the Nepsilon atom of His317. The oxygen atom attached to the tetrahedral carbon in the thiohemiacetal group of the inhibitor is hydrogen bonded to Ndelta of His317, and is not in a region characteristic of a classical 'oxyanion hole'. The N-acetyl group of the inhibitor is in the trans configuration. The caspase-8-inhibitor structure provides the basis for understanding structure/function relationships in this important initiator of the proteolytic cascade that leads to programmed cell death.
Assuntos
Apoptose/fisiologia , Caspases/química , Caspases/metabolismo , Sequência de Aminoácidos , Sítios de Ligação , Caspase 8 , Caspase 9 , Inibidores de Caspase , Domínio Catalítico , Cristalografia por Raios X/métodos , Inibidores de Cisteína Proteinase/química , Inibidores de Cisteína Proteinase/metabolismo , Dimerização , Humanos , Modelos Moleculares , Dados de Sequência Molecular , Oligopeptídeos/química , Oligopeptídeos/metabolismo , Conformação Proteica , Proteínas Recombinantes/química , Proteínas Recombinantes/genética , Homologia de Sequência de AminoácidosRESUMO
This review deals with clinical applications of compounds that inhibit the action of the protease encoded within the genome of human immunodeficiency virus (HIV). The HIV-protease is essential for viral maturation and represents an important therapeutic target in the fight against AIDS. Following a brief overview of the enzyme structure and function, the article focuses on a number of peptide and non-peptide based HIV-protease inhibitors that are in current clinical use. These drugs are discussed both with respect to their efficacy in treatment of AIDS, and to problems related to insurgence of viral resistance and side effects seen to date in patient populations.
Assuntos
Síndrome da Imunodeficiência Adquirida/tratamento farmacológico , Fármacos Anti-HIV/uso terapêutico , Inibidores da Protease de HIV/uso terapêutico , Protease de HIV/genética , HIV-1/enzimologia , Síndrome da Imunodeficiência Adquirida/virologia , Fármacos Anti-HIV/efeitos adversos , Sítios de Ligação , Carbamatos , Ensaios Clínicos como Assunto , Desenho Assistido por Computador , Cristalografia por Raios X , Desenho de Fármacos , Resistência Microbiana a Medicamentos/genética , Quimioterapia Combinada , Furanos , Protease de HIV/química , Inibidores da Protease de HIV/efeitos adversos , HIV-1/genética , Humanos , Indinavir/uso terapêutico , Nelfinavir/química , Nelfinavir/uso terapêutico , Oligopeptídeos/uso terapêutico , Piridinas/química , Piridinas/uso terapêutico , Pironas/química , Pironas/uso terapêutico , Ensaios Clínicos Controlados Aleatórios como Assunto , Ritonavir/uso terapêutico , Saquinavir/uso terapêutico , Sulfonamidas/química , Sulfonamidas/uso terapêuticoRESUMO
Adenylate kinase from yeast cytosol was crystallized as a 1:1 complex with the inhibitor P1,P5-di(adenosine-5'-)pentaphosphate. The crystalline structure was solved by multiple isomorphous replacement at a resolution of 3 A (1 A = 0.1 nm) and subsequent structural refinement at 2.6 A resolution. The yeast enzyme belongs to the group of large variants among the adenylate kinases, whereas the structurally known porcine cytosolic enzyme is a small variant. A comparison showed that the additional 31-residue segment of the large variants covers the active center. This had not been expected, because small and large variants show similar enzyme kinetics. Apart from this insertion, the chain folds of both adenylate kinases are the same. The yeast enzyme with bound inhibitor, however, assumes a much more closed form. In relation to the porcine enzyme without substrate, a segment of 28 residues containing two helices is rotated by about 30 degrees, closing the deep cleft at the active center. This corresponds to the expected induced fit. Sequence comparisons with other adenylate kinases suggest that one of the adenosine moieties of the inhibitor does not bind at a native nucleotide-binding site of the enzyme.
Assuntos
Nucleotídeos de Adenina/farmacologia , Adenilato Quinase/antagonistas & inibidores , Fosfatos de Dinucleosídeos , Fosfotransferases/antagonistas & inibidores , Saccharomyces cerevisiae/enzimologia , Sítios de Ligação , Cristalização , Substâncias Macromoleculares , Modelos Moleculares , Conformação Proteica , Difração de Raios XRESUMO
Crystals of GTP: AMP phosphotransferase from beef heart mitochondria suitable for X-ray analysis have been grown. They belong to space group I4 with unit cell dimensions: a = b = 88.2 A, c = 147.8 A. The asymmetric unit contains two molecules each of Mr = 26,000. So far, two heavy-atom derivatives have been obtained.
Assuntos
Núcleosídeo-Fosfato Quinase , Fosfotransferases , Animais , Bovinos , Cristalização , Mitocôndrias Cardíacas/enzimologia , Difração de Raios XRESUMO
A study has been made of the susceptibility of recombinant constructs of reverse transcriptase (RT) and ribonuclease H (RNase H) from human immunodeficiency virus type 1 (HIV-1) to digestion by the HIV-1 protease. At neutral pH, the protease attacks a single peptide bond, Phe440-Tyr441, in one of the protomers of the folded, active RT/RNase H (p66/p66) homodimer to give a stable, active heterodimer (p66/p51) that is resistant to further hydrolysis (Chattopadhyay, D., et al., 1992, J. Biol. Chem. 267, 14227-14232). The COOH-terminal p15 fragment released in the process, however, is rapidly degraded by the protease by cleavage at Tyr483-Leu484 and Tyr532-Leu533. In marked contrast to this p15 segment, both p66/p51 and a folded RNase H construct are stable to breakdown by the protease at neutral pH. It is only at pH values around 4 that these latter proteins appear to unfold and, under these conditions, the heterodimer undergoes extensive proteolysis. RNase H is also hydrolyzed at low pH, but cleavage takes place primarily at Gly436-Ala437 and at Phe440-Tyr441, and only much more slowly at residues 483, 494, and 532. This observation can be reconciled by inspection of crystallographic models of RNase H, which show that residues 483, 494, and 532 are relatively inaccessible in comparison to Gly436 and Phe440. Our results fit a model in which the p66/p66 homodimer exists in a conformation that mirrors that of the heterodimer, but with a p15 segment on one of the protomers that is structurally disordered to the extent that all of its potential HIV protease cleavage sites are accessible for hydrolysis.
Assuntos
Protease de HIV/metabolismo , HIV-1/enzimologia , DNA Polimerase Dirigida por RNA/metabolismo , Ribonuclease H/metabolismo , Sequência de Aminoácidos , Transcriptase Reversa do HIV , Concentração de Íons de Hidrogênio , Hidrólise , Modelos Moleculares , Dados de Sequência Molecular , Conformação Proteica , Desnaturação Proteica , Proteínas Recombinantes/metabolismo , Homologia de Sequência de Aminoácidos , Especificidade por SubstratoRESUMO
The structure of a crystal complex of recombinant human immunodeficiency virus type 1 (HIV-1) protease with a peptide-mimetic inhibitor containing a dihydroxyethylene isostere insert replacing the scissile bond has been determined. The inhibitor is Noa-His-Hch psi [CH(OH)CH(OH)]Vam-Ile-Amp (U-75875), and its Ki for inhibition of the HIV-1 protease is < 1.0 nM (Noa = 1-naphthoxyacetyl, Hch = a hydroxy-modified form of cyclohexylalanine, Vam = a hydroxy-modified form of valine, Amp = 2-pyridylmethylamine). The structure of the complex has been refined to a crystallographic R factor of 0.169 at 2.0 A resolution by using restrained least-squares procedures. Root mean square deviations from ideality are 0.02 A and 2.4 degrees, for bond lengths and angles, respectively. The bound inhibitor diastereomer has the R configurations at both of the hydroxyl chiral carbon atoms. One of the diol hydroxyl groups is positioned such that it forms hydrogen bonds with both the active site aspartates, whereas the other interacts with only one of them. Comparison of this X-ray structure with a model-built structure of the inhibitor, published earlier, reveals similar positioning of the backbone atoms and of the side-chain atoms in the P2-P2' region, where the interaction with the protein is strongest. However, the X-ray structure and the model differ considerably in the location of the P3 and P3' end groups, and also in the positioning of the second of the two central hydroxyl groups. Reconstruction of the central portion of the model revealed the source of the hydroxyl discrepancy, which, when corrected, provided a P1-P1' geometry very close to that seen in the X-ray structure.
Assuntos
Antivirais/química , Inibidores da Protease de HIV/química , Protease de HIV/química , Oligopeptídeos/farmacologia , Conformação Proteica , Sequência de Aminoácidos , Antivirais/farmacologia , Sítios de Ligação , Protease de HIV/metabolismo , Inibidores da Protease de HIV/farmacologia , HIV-1/enzimologia , Cinética , Modelos Moleculares , Dados de Sequência Molecular , Estrutura Molecular , Oligopeptídeos/química , Proteínas Recombinantes/antagonistas & inibidores , Proteínas Recombinantes/química , Difração de Raios XRESUMO
To complete the amino acid sequence of GTP:AMP phosphotransferase (MgGTP + AMP in equilibrium with MgGDP + ADP) from beef heart mitochondria it was necessary to sequence an intermediate region of about 33 residues after position 102 [(1984) Eur. J. Biochem. 143, 331-339] and find a suitable overlap with the rest of the protein. The required peptides were obtained by cleaving the enzyme with endoproteinase Lys-C. One peptide, covering the region from residue 79 to 144, was sequenced up to residue 124. Another peptide, extending from residue 79 to 169, was subcleaved with Staphylococcus aureus V8 protease and provided the fragment from residue 99 to 139 which was sequenced. Several other peptides from endoproteinase Lys-C cleavage were used to check large sections of the previously published sequence work. The complete sequence contains 225 amino acids and has an Mr of 25 469.
Assuntos
Metaloendopeptidases , Mitocôndrias Cardíacas/enzimologia , Núcleosídeo-Fosfato Quinase , Fosfotransferases/análise , Serina Endopeptidases , Sequência de Aminoácidos , Aminoácidos/análise , Animais , Bovinos , Cromatografia Líquida de Alta Pressão , Endopeptidases/metabolismo , Peso Molecular , Fragmentos de Peptídeos/análiseRESUMO
Apoptosis, or programmed cell death, plays a central role in the development and homeostasis of an organism. The breakdown of cellular proteins in apoptosis is mediated by caspases, which comprise a highly conserved family of cysteine proteases with specificity for aspartic acid residues at the P1 positions of their substrates. Multiple lines of evidence show that caspase-9 is critical for an apoptosis pathway mediated via the mitochondria. In this study, the three-dimensional structure of the catalytic domain of caspase-9 and its interaction with the inhibitor acetyl-Asp-Val-Ala-Asp fluoromethyl ketone (Ac-DVAD-fmk) have been predicted by a segment matching modeling procedure. As expected, the predicted caspase-9 structure shows both a high similarity in the overall folding topology and remarkable differences in the surface loop regions as compared to other caspase family members such as caspase-1, -3 and -8, for which crystal structures have been determined. This kind of comparative analysis reflects the convergence-divergence duality among the caspases. Moreover, some subtle differences have been observed between caspase-9 and caspase-3 in the subsite contacts with the covalently linked inhibitor Ac-DVAD-fmk. Based on the X-ray structural analysis of caspase-8, a main chain carbonyl oxygen appears to be involved in a catalytic triad with the active site Cys and His residues. The corresponding carbonyl oxygen in caspase-9, together with other expected features of the catalytic apparatus, appears in our model. The predicted structure of caspase-9 can serve as a reference for subsite analysis relative to rational design of highly selective caspase inhibitors for therapeutic application.
Assuntos
Clorometilcetonas de Aminoácidos/química , Clorometilcetonas de Aminoácidos/metabolismo , Inibidores de Caspase , Caspases/química , Domínio Catalítico , Modelos Moleculares , Sequência de Aminoácidos , Sítios de Ligação , Caspase 9 , Caspases/metabolismo , Simulação por Computador , Sequência Conservada , Cristalografia por Raios X , Ligação de Hidrogênio , Dados de Sequência Molecular , Oxigênio/metabolismo , Estrutura Secundária de Proteína , Estrutura Terciária de Proteína , Alinhamento de SequênciaRESUMO
The peptidomimetic template and the dihydroxyethylene isostere insert that were applied successfully to the design of renin inhibitors have been extended to the related protease from human immunodeficiency virus (HIV). The present report describes the structure-activity study leading to the identification of an inhibitor with a Ki of less than 1 nM for the HIV type-1 protease (compound II). This compound, containing a diol insert, is highly effective in blocking polyprotein processing in in vitro cell culture assays. Results obtained from kinetic analysis, studies of the stereochemistry of the insert, and modeling have led to insights as to the requisites involved in the active site-inhibitor interaction.
Assuntos
Antivirais/farmacologia , Desenho de Fármacos , Inibidores da Protease de HIV , Oligopeptídeos/síntese química , Oligopeptídeos/farmacologia , Sequência de Aminoácidos , Antivirais/química , Antivirais/metabolismo , Sítios de Ligação , Fenômenos Químicos , Química , Dipeptídeos/síntese química , Protease de HIV/metabolismo , HIV-1/enzimologia , Modelos Moleculares , Dados de Sequência Molecular , Estrutura Molecular , Oligopeptídeos/química , Oligopeptídeos/metabolismo , Conformação Proteica , Relação Estrutura-Atividade , Difração de Raios XRESUMO
The low oral bioavailability and rapid biliary excretion of peptide-derived HIV protease inhibitors have limited their utility as potential therapeutic agents. Our broad screening program to discover nonpeptidic HIV protease inhibitors had previously identified compound II (phenprocoumon, K(i) = 1 muM) as a lead template. Crystal structures of HIV protease complexes containing the peptide-derived inhibitor I (1-(naphthoxyacetyl)-L-histidyl-5(S)-amino-6-cyclohexyl-3 (R),4(R)-dihydroxy-2(R)-isopropylhexanoyl-L-isoleucine N-(2-pyridylmethyl)amide) and nonpeptidic inhibitors, such as phenprocoumon (compound II), provided a rational basis for the structure-based design of more active analogues. This investigation reports on the important finding of a carboxamide functionally appropriately added to the 4-hydroxycoumarin and the 4-hydroxy-2-pyrone templates which resulted in a new promising series of nonpeptidic HIV protease inhibitors with improved enzyme-binding affinity. The most active diastereomer of the carboxamide-containing compound XXIV inhibited HIV-1 protease with a K(i) value of 0.0014 muM. This research provides a new design direction for the discovery of more potent HIV protease inhibitors as potential therapeutic agents for the treatment of HIV infection.
Assuntos
4-Hidroxicumarinas/farmacologia , Inibidores da Protease de HIV/farmacologia , HIV-1/enzimologia , Pironas/farmacologia , 4-Hidroxicumarinas/química , Sequência de Aminoácidos , Sítios de Ligação , Linhagem Celular , Gráficos por Computador , Cristalografia por Raios X , Inibidores da Protease de HIV/química , HIV-2/enzimologia , Humanos , Dados de Sequência Molecular , Pironas/química , Relação Estrutura-AtividadeRESUMO
A number of potential HIV protease inhibitory peptides that contain the dihydroxyethylene isostere were prepared and evaluated for their enzyme binding affinity and antiviral activity in cell cultures. From the template of a previously reported active peptide A, modifications at the N- and C-terminal groups were assessed for potential maintenance of good inhibitory activity of the resulting peptides. Among the active peptides found, peptide XVIII exhibited potent enzyme inhibitory activity. Interestingly, the previously reported, effective 1(S)-amino-2(R)-hydroxyindan C-terminal group for the preparation of very active HIV protease inhibitory peptides could not be applied to the template of peptide XVIII. Molecular modeling of peptide XVIII was studied using the X-ray crystal structure of peptide A as a starting point in order to study the likely conformation of peptide XVIII in the active-site cleft. Relative binding conformations of peptide A and XVIII were obtained, although the reason for poor binding affinity for a number of congeneric peptides in this report was not straightforwardly apparent. More importantly, however, peptide XVIII was found to exhibit more effective antiviral activity in the HIV-1/PBMC assay than the reference peptide A which was previously reported to be approximately equal in efficacy to the reverse transcriptase inhibitor AZT in this assay.
Assuntos
Antivirais/síntese química , Inibidores da Protease de HIV/síntese química , Animais , Antivirais/química , Antivirais/farmacologia , Células Cultivadas , Etilenos/síntese química , Etilenos/química , Etilenos/farmacologia , Inibidores da Protease de HIV/química , Inibidores da Protease de HIV/farmacologia , Haplorrinos , Humanos , Modelos Moleculares , Conformação Molecular , RNA Viral/efeitos dos fármacos , Relação Estrutura-AtividadeRESUMO
Actin, one of the most abundant proteins of the cell, is hydrolyzed by the human immunodeficiency virus type 1 (HIV-1) protease during acute infection of cultured human T lymphocytes. The actin fragments produced during the course of infection are identical to those obtained by recombinant HIV-1 protease digests of (1) a lysate from uninfected T lymphocytes and (2) globular actin itself. Hydrolysis by the HIV-1 protease of physiologically important host cellular proteins during infection may have important consequences relative to viral pathogenesis.
Assuntos
Actinas/metabolismo , Protease de HIV/metabolismo , HIV-1/enzimologia , Linhagem Celular , Eletroforese em Gel Bidimensional , HIV-1/fisiologia , Humanos , Hidrólise , Linfócitos T/microbiologiaAssuntos
Clorometilcetonas de Aminoácidos/farmacologia , Esclerose Lateral Amiotrófica/tratamento farmacológico , Inibidores de Caspase , Neurônios Motores/efeitos dos fármacos , Fármacos Neuroprotetores/farmacologia , Clorometilcetonas de Aminoácidos/uso terapêutico , Esclerose Lateral Amiotrófica/enzimologia , Esclerose Lateral Amiotrófica/patologia , Animais , Apoptose/efeitos dos fármacos , Caspase 1/metabolismo , Caspase 3 , Caspases/metabolismo , Inibidores de Cisteína Proteinase/farmacologia , Inibidores de Cisteína Proteinase/uso terapêutico , Modelos Animais de Doenças , Humanos , Interleucina-1/metabolismo , Camundongos , Camundongos Transgênicos , Neurônios Motores/patologia , Fármacos Neuroprotetores/uso terapêutico , Medula Espinal/efeitos dos fármacos , Medula Espinal/enzimologia , Medula Espinal/patologia , Superóxido Dismutase/genética , Superóxido Dismutase/metabolismo , Superóxido Dismutase-1RESUMO
Scheme 1 summarizes some of what we have learned from this study of non-viral protein substrates of the HIV proteases. Many of these findings contradict the current understanding of protease specificity. P1-P1' amino acids need not be bulky or hydrophobic and residues at these positions may be even less important than those in flanking positions (e.g., Glu at P2') in dictating the course of hydrolysis. Thus, the pattern of amino acids over the whole binding region must be considered in predicting what will or will not be a substrate of these enzymes and, although we are beginning to understand selectivity at the level of primary structure, a detailed explanation of their specificity is yet to be forthcoming. Nevertheless, studies of this kind find useful application in the design of inhibitors of HIV proteases that will, hopefully, be of value in treatment of AIDS.